X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will fund research and development of company's vaccine programs, including Granite, a personalized neoantigen-based vaccine, being evaluated in a Phase 2/3 study in patients with newly diagnosed, metastatic microsatellite-stable colorectal cancer.
Lead Product(s): GRT-C901,GRT-R902,Bevacizumab
Therapeutic Area: Oncology Product Name: Granite
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: TD Cowen
Deal Size: $32.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 01, 2024
Details:
Granite (GRT-C901/GRT-R902) is patient-specific neoantigen cancer vaccine. It is being evaluated in combination with immune checkpoint blockade in addition to fluoropyrimidine/bevacizumab for the treatment of front-line metastatic microsatellite stable colorectal cancer.
Lead Product(s): GRT-C901,GRT-R902,Bevacizumab
Therapeutic Area: Oncology Product Name: Granite
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
The net proceeds from the funding will be used by Gritstone for the advancement of Phase 2 study for GRT-R910, a self-amplifying mRNA vaccine candidate.
Lead Product(s): GRT-R910
Therapeutic Area: Infections and Infectious Diseases Product Name: GRT-R910
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: U.S. Department of Health and Human Services
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Funding October 13, 2023
Details:
The net proceeds will be used to conduct a Phase 2b comparative study evaluating Gritstone’s self-amplifying mRNA (samRNA) vaccine candidate, GRT-R910, containing Spike plus other viral targets to protect against COVID-19.
Lead Product(s): GRT-R910
Therapeutic Area: Infections and Infectious Diseases Product Name: GRT-R910
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: BARDA
Deal Size: $433.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 27, 2023
Details:
Under the agreement, Gritstone will have a multi-year option for a non-exclusive license under Genevant’s LNP technology on a pathogen-by-pathogen basis to develop and commercialize self-amplifying RNA (samRNA) vaccines.
Lead Product(s): samRNA Vaccine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Recipient: Genevant Sciences
Deal Size: $136.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 15, 2023
Details:
GRT-R910 is the vaccine is expected to boost and expand first-generation Covid-19 vaccines’ immunogenicity in people aged 60 years and above. GRT-R910 utilises a SAM vector formulated with lipid nanoparticles to deliver antigens against SARS-CoV-2 spike protein.
Lead Product(s): GRT-R910
Therapeutic Area: Infections and Infectious Diseases Product Name: GRT-R910
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
Under the terms of the agreement, NCI will identify patients with metastatic cancer that are eligible for adoptive cell transfer based on the presence of a G12V or G12D KRAS mutation (KRASmut).
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: SLATE-KRAS
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 14, 2023
Details:
Gritstone’s samRNA vectors enable extended duration and magnitude of antigen expression, in an immunostimulatory context, which together can drive more potent and durable induction of neutralizing antibodies and T cell immunity.
Lead Product(s): GRT-C901,GRT-R902,Atezolizumab
Therapeutic Area: Oncology Product Name: GRT-C901
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
Gritstone intends to use the net proceeds from the PIPE financing to fund the ongoing clinical development of oncology and infectious disease programs including GRT-C901 and for general corporate purposes.
Lead Product(s): GRT-C901,GRT-R902,Atezolizumab
Therapeutic Area: Oncology Product Name: GRT-C901
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Redmile Group
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 25, 2022
Details:
New data from CORAL-BOOST study for samRNA Covid-19 Vaccine demonstrate broad and durable immune response; high neutralizing antibody and T cell responses at 6 months post-boost vaccination.
Lead Product(s): samRNA Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
